Next Article in Journal
Computational Screening for the Anticancer Potential of Seed-Derived Antioxidant Peptides: A Cheminformatic Approach
Next Article in Special Issue
Novel Small-Molecule Hybrid-Antibacterial Agents against S. aureus and MRSA Strains
Previous Article in Journal
A Computational Journey across Nitroxide Radicals: From Structure to Spectroscopic Properties and Beyond
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 26
Issue 23
10.3390/molecules26237400
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Enhancement of Antibiotic Activity by 1,8-Naphthyridine Derivatives against Multi-Resistant Bacterial Strains

by
José B. de Araújo-Neto
1,
Maria M. C. da Silva
1,
Cícera D. de M. Oliveira-Tintino
1,
Iêda M. Begnini
2,
Ricardo A. Rebelo
2,
Luiz E. da Silva
3,
Sandro L. Mireski
2,
Michele C. Nasato
2,
Maria I. L. Krautler
2,
Jaime Ribeiro-Filho
4,
Abolghasem Siyadatpanah
5,6,*,
Polrat Wilairatana
7,*,
Henrique D. M. Coutinho
1,* and
Saulo R. Tintino
1
1
Laboratory of Microbiology and Molecular Biology (LMBM), Regional University of Cariri—URCA, Crato 63105-000, CE, Brazil
2
Department of Chemistry, Regional University of Blumenau—FURB, Itoupava Seca, Blumenau 89012-900, SC, Brazil
3
Postgraduate Program in Sustainable Territorial Development—Coastal Sector, Federal University of Paraná, Curitiba 80060-000, PR, Brazil
4
Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Rua Waldemar Falcão, 121, Candeal, Salvador 40296-710, BA, Brazil
5
Ferdows School of Paramedical and Health, Birjand University of Medical Sciences, Birjand 9717853577, Iran
6
Infectious Diseases Research Center, Birjand University of Medical Sciences, Birjand 9717853577, Iran
7
Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
*
Authors to whom correspondence should be addressed.
Molecules 2021, 26(23), 7400; https://doi.org/10.3390/molecules26237400
Submission received: 16 November 2021 / Revised: 2 December 2021 / Accepted: 4 December 2021 / Published: 6 December 2021
(This article belongs to the Special Issue Researches on Novel Antibacterial Agents)
Browse Figures
Versions Notes

Abstract

:
The search for new antibacterial agents has become urgent due to the exponential growth of bacterial resistance to antibiotics. Nitrogen-containing heterocycles such as 1,8-naphthyridine derivatives have been shown to have excellent antimicrobial properties. Therefore, the purpose of this study was to evaluate the antibacterial and antibiotic-modulating activities of 1,8-naphthyridine derivatives against multi-resistant bacterial strains. The broth microdilution method was used to determine the minimum inhibitory concentration (MIC) of the following compounds: 7-acetamido-1,8-naphthyridin-4(1H)-one and 3-trifluoromethyl-N-(5-chloro-1,8-naphthyridin-2-yl)-benzenesulfonamide. The antibiotic-modulating activity was analyzed using subinhibitory concentrations (MIC/8) of these compounds in combination with norfloxacin, ofloxacin, and lomefloxacin. Multi-resistant strains of Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus were used in both tests. Although the compounds had no direct antibacterial activity (MIC ≥ 1.024 µg/mL), they could decrease the MIC of these fluoroquinolones, indicating synergism was obtained from the association of the compounds. These results suggest the existence of a structure–activity relationship in this group of compounds with regard to the modulation of antibiotic activity. Therefore, we conclude that 1,8-naphthyridine derivatives potentiate the activity of fluoroquinolone antibiotics against multi-resistant bacterial strains, and thereby interesting candidates for the development of drugs against bacterial infections caused by multidrug resistant strains.

1. Introduction

Bacterial diseases have been associated with high mortality rates at various times in history, and the discovery of substances with potential for preventing and healing bacterial infections has had a significant impact on science and public health [1]. In this context, antibiotics are crucial products for modern medicine, contributing to increased life expectancy and reduced child mortality. They also have fundamental applications in surgical processes and chemotherapy [2].
Multidrug resistance in bacteria has become a global epidemic [3]. Pseudomonas aeruginosa (P. aeruginosa), Escherichia coli (E. coli), and Staphylococcus aureus (S. aureus) are opportunistic pathogens that are among the most clinically and epidemiologically relevant multi-resistant bacteria [4]. Bacterial resistance mechanisms can be classified as intrinsic or acquired. While intrinsic mechanisms are related to structural or functional characteristics of the microorganism, acquired mechanisms result from mutations or horizontal gene transfer [5,6].
The management of infections caused by multi-resistant microorganisms is challenging because the emergence of new resistant organisms every day demands the development of new antibacterial compounds since current antibiotics are not enough [7]. The search for bioactive substances has identified a class of molecules with enormous therapeutic potential known as heterocyclic compounds [8]. This class of molecules represents about half of all known compounds including drugs, vitamins, and bioactive metabolites of plants and marine organisms [9].
Heterocyclic compounds are estimated to account for about 62% of active pharmaceutical ingredients. Among these substances, 91% are nitrogen-containing compounds. Nitrogen-containing heterocycles include both chemically synthesized and naturally occurring compounds such as 1,8-naphthyridine derivatives [10]. Studies have shown that these compounds have various biological activities such as antibacterial [11], antifungal [12], antiviral [13], anti-inflammatory [14], antitumor [15], and analgesic [16], and are therefore promising candidates for the development of new drugs.
Therefore, the present study aimed to evaluate the antibacterial and antibiotic-modulating activity of 1,8-naphthyridine derivatives against multi-resistant bacterial strains.

2. Results

2.1. Antibacterial Activity

An analysis of the antibacterial activity of 7-acetamido-1,8-naphthyridin-4(1H)-one (1,8-NA) and 3-trifluoromethyl-N-(5-chloro-1,8-naphthyridin- 2-yl)-benzenesulfonamide (3-TNB) against the multi-resistant strains E. coli 06, S. aureus 10, and P. aeruginosa 24 revealed that both compounds had minimum inhibitory concentrations (MICs) ≥ 1.024 µg/mL against all tested strains, indicating that they have no clinically relevant antibacterial activity.

2.2. Antibiotic-Modulating Activity

Having demonstrated that 1,8-NA presented no clinically relevant antibacterial activity against any of the strains tested, we evaluated the modulatory action of this substance in combination with norfloxacin, ofloxacin, and lomefloxacin fluoroquinolones. As shown in Figure 1, in the presence of subinhibitory concentrations of 1,8-NA, all antibiotics showed significantly reduced MICs against multi-resistant strains S. aureus 10, P. aeruginosa 24, and E. coli 06, indicating that the combination of antibiotics with the 1,8-naphthyridine derivative showed synergism with regard to the antibacterial activity. The greatest reductions in antibiotic MICs occurred with ofloxacin (32 to 4 µg/mL) and lomefloxacin (16 to 2 µg/mL), both against E. coli 06.
Similarly, the combination of 3-TNB with antibiotics under the same conditions described above caused a significant reduction in MIC of these drugs, except for the association with lomefloxacin against P. aeruginosa 24 (Figure 2). The greatest reduction occurred in the MIC of lomefloxacin (16 to 3.2 µg/mL) against E. coli 06. Taken together, our results indicate that the 1,8-naphthyridine derivatives evaluated by the present study are capable of modulating fluoroquinolone activity against both Gram-positive and Gram-negative multi-resistant bacteria.

3. Discussion

Due to a broad spectrum of biological actions previously mentioned, 1,8-naphthyridine derivatives have gained increasing importance in the fields of medicinal chemistry and drug development. Studies indicate that these compounds have enormous potential for the synthesis of new molecules, which has been associated with the structure–activity relationship in several biological models [11,12,13,14,15,16]. Furthermore, molecular modifications can be used to improve the physicochemical properties of these substances, generating compounds with optimized therapeutic effects [8,9,10].
The study carried out by Abu-Melha et al. [17] evaluated the antimicrobial potential of nitrogen-containing synthetic heterocycles and demonstrated that these compounds did not have a direct antibacterial action. According to the authors, using the agar diffusion method, no clinically relevant antibacterial activity was detected against S. aureus and E. coli given the fact that the MICs of the compounds were higher than the MIC of the gentamicin control (aminoglycoside). Studies with naphthyridine compounds showed similar results, with no significant antibacterial activity being obtained, which corroborates the data obtained in the present study [18,19]. Here, we demonstrated that the 1,8-naphthyridine derivatives 1,8-NA and 3-TNB presented MICs ≥1.024 µg/mL, and as such, are not promising antibacterial agents, as a higher concentration could lead to significant toxicity [20].
Insertion of fluoroquinolones as antibacterial agents in the last century has represented a breakthrough in antibiotic therapy, mainly due to their efficacy in combating infectious diseases [21]. Although these drugs were initially used only for the treatment of Gram-negative bacterial infections, the improvement in their properties allowed for the therapeutic use of these drugs to treat Gram-positive infections [22]. These antibiotics inhibit the activity of DNA gyrase (or topoisomerase II), an enzyme that is essential for bacterial survival. This enzyme acts by making the DNA molecule compact and biologically active. Thus, when this enzyme is inhibited, the DNA molecule free ends determine the uncontrolled synthesis of messenger RNA and proteins, causing bacterial death [23].
The data described by the present study demonstrate that fluoroquinolone association with 1,8-NA and 3-TNB significantly enhanced the antibacterial action of this class of antibiotics. This further suggests that 1,8-naphthyridine derivatives and antibiotics interact chemically, resulting in a synergistic antibacterial action. In fact, the radicals of these compounds can interact with various sites in the bacterial cellular environment. In addition, it is important to mention that 1,8-NA is employed in the synthesis of 1,8-naphthyridines such as 3-TNB [24], from which nalidixic acid was synthesized. This compound was a prototype for quinolones, which posteriorly originated fluoroquinolones [25].
A study showed that 1,5-naphthyridinone derivatives act by inhibiting bacterial topoisomerase, causing bacterial death [26]. Another study also reported on enzymatic inhibition as a potential antibacterial effect of naphthyridinones against strains of E. coli and S. aureus [27]. Eweas et al. [28] showed that 1,8-naphthyridine derivatives have the ability to bind topoisomerase II enzymes and can inhibit them as well as fluoroquinolones. These findings support the evidence of a synergistic interaction between 1,8-NA and 3-TNB with fluoroquinolones based on their similar antibacterial mechanisms of action.
In addition to the research cited, using in silico studies, Gençer et al. [29] demonstrated that 1,8-naphthyridine derivatives inhibit DNA gyrase (topoisomerase) such as fluoroquinolones, and through in vitro studies, they obtained a significant antibacterial effect against Gram-positive and Gram-negative strains. However, the authors worked with strains susceptible to antibiotics, which explains the difference in the results above-mentioned and gives us clues that the structural similarity between the 1,8-naphthyridine derivatives and the fluoroquinolones causes some resistance to the tested compounds.
Da Silva et al. [30], using the same bacterial strains and antibiotics of the present research, demonstrated that the Meldrum’s acid arylamino methylene derivative N-{6-[(2,2-dimethyl-4,6-dioxo-[1,3]-dioxane-5-ylidenomethyl)-amino]-pyridin-2-yl}-acetamide enhanced the effect of fluoroquinolones, attributing the synergistic effect to the similarity between the mechanism of action of its compound and the respective antibiotics. In addition to the fact that 1,8-naphthyridine derivatives and fluoroquinolones share similarities in chemical structure and mechanism of action on bacteria, these derivatives have been shown to inhibit bacterial resistance mechanisms [31]. Efflux pumps are transmembrane proteins that remove compounds toxic to bacteria from the intracellular medium and are one of the main mechanisms of resistance to fluoroquinolones [32]. 1,8-Naphthyridine derivatives have already been reported as inhibitors of NorA and MepA efflux pumps, which efflux norfloxacin and ciprofloxacin, respectively [33,34]. These results provide new insights into the antibiotic-modulating activity of 1,8-naphthyridine derivatives demonstrated in the present research.
Naphthyridines may occur in six different isomeric forms: 1,5-naphthyridine, 1,6-naphthyridine, 1,7-naphthyridine, 1,8-naphthyridine, 2,6-naphthyridine, and 2,7-naphthyridine [25]. Among these, due to scientifically proven biological activities, 1,8-naphthyridines are the most studied. It was indicated that these compounds have a wide variety of biological activities such as antiparasitic, antibacterial, anti-inflammatory, antiallergic, and antitumor [35]. According to Leonard et al. [36], these compounds stand out for their antimicrobial potential, which can be potentiated by the combination with sulfonamides [37].
Our research group has shown that the association between different substances does not always result in potentiated antibacterial activity. In fact, drug combinations can result in reduced drug bioactivity, either by mutual chelation [38], or by competition for the binding site in the microorganism [39]. In this case, an increased minimum inhibitory concentration was observed, indicating that the association has no clinical benefit. Some associations, however, are neutral (i.e., there is no synergism or antagonism) [40]. This phenomenon could explain the results obtained from the combination of lomefloxacin with naphthyridine 3-TNB against P. aeruginosa, which was found to be an exception to the significant antibiotic-modulating effects exerted by 1,8-naphthyridine derivatives in the present study.

4. Materials and Methods

4.1. Obtaining and Preparation of Nitrogen-Containing Heterocycles and Antibiotics

The following compounds: 7-Acetamido-1,8-naphthyridin-4(1H)-one (1,8-NA) and 3-trifluoromethyl-N-(5-chloro-1,8-naphthyridin-2-yl)-benzenesulfonamide (3-TNB) (Figure 3), provided by Dr. Luiz Everson da Silva of the Federal University of Paraná, were obtained by chemical synthesis. The FTIR SPECTRUM, NMR 1H and 13C besides 19F of 7-Acetamido-1,8-naphthyridin-4(1H)-one (1,8-NA) and 3-trifluoromethyl-N-(5-chloro-1,8-naphthyridin-2-yl)-benzenesulfonamide (3-TNB) are supplied in the Supplementary Materials. The chemical synthesis occurred from the thermolysis of Meldrum’s acid adduct. The final sulfonamide derivatives were obtained by sulfonylation of 2-amino-5-chloro-1,8-naphthyridine with different commercial benzenesulfonyl chlorides [34].
The fluoroquinolones norfloxacin, ofloxacin, and lomefloxacin (Figure 4) were purchased from SIGMA Chemical (St. Louis, MI, USA), and were chosen for their strong relationship with the tested compounds, which are their precursors. A total of 10 mg of each substance was diluted in 1 mL of dimethyl sulfoxide (DMSO) to a concentration of 10 mg/mL, which was diluted in sterile distilled water to a 1.024 µg/mL [41].

4.2. Bacterial Strains and Preparation of Inocula

The following multi-resistant strains were used in the tests: E. coli 06, S. aureus 10, and P. aeruginosa 24. The origin and resistance profile of these strains were described by Bezerra et al. [42]. These bacteria were supplied by the Laboratory of Microbiology and Molecular Biology (LMBM) of the Regional University of Cariri (URCA), kept on blood agar (Laboratory Difco Ltd., Crato, Brazil) and cultured in heart infusion agar medium (HIA, Difco. Laboratorises Ltd.) at 37 °C for 24 h.
Inocula were prepared by taking a sample from the corresponding culture and adding it to tubes containing 5 mL of sterile saline (0.9% NaCl). The tubes containing the bacterial suspensions were shaken, and their turbidities were compared to the 0.5 McFarland scale, corresponding to 1.5 × 108 colony forming units (CFU)/mL [43].

4.3. Minimum Inhibitory Concentration (MIC)

Following the methodology of Javadpour et al. [44], 100 µL of the inoculum was added to tubes containing 900 µL of the 10% BHI (Brain Heart Infusion Broth). Aliquots of 100 µL of each solution were transferred to a 96-well plate, followed by serial dilution (1:1) of the compounds to reach concentrations ranging from 512 to 8 µg/mL in the plates. The last well was added with the inoculum in the absence of treatment and was used as bacterial growth control. The assays were performed in triplicate, and plates were incubated in a bacterial greenhouse at 37 °C. After 24 h, 20 µL of resazurin (7-hydroxy-3H-phenoxazine-3-one-10-oxide) at 0.4 mg/mL was added to each well and, after 1 h at 25 °C, a color change from blue to pink indicated bacterial growth, by redox reaction, with the reaction of acid released by the bacteria with resazurin.

4.4. Evaluation of the Antibiotic-Modulating Activity

Briefly, 1.162 µL of 10% BHI, 150 µL of inoculum from each strain, and a volume of the compound corresponding to the subinhibitory concentration (MIC/8 = 128 µg/mL) were added to test tubes, and a subinhibitory concentration was used to assess whether the substances potentiated the effect of fluoroquinolones. Modulation controls were prepared using only 1.350 µL of 10% BHI medium and 150 µL of inoculum. The contents of each tube were distributed in 96-well plates (100 µL/well). Microdilution (1:1) was performed by adding 100 µL of each antibiotic whose concentrations in the plates ranged from 512 to 0.5 µg/mL [45]. The tests were performed in triplicate and the plates incubated at 37 °C for 24 h. Readings were taken 1 h after the addition of resazurin, as previously described.

4.5. Statistical Analysis

The means of the three repetitions were submitted to two-way analysis of variance (ANOVA) followed by Bonferroni’s post-hoc test using GraphPad Prism software, version 5.0. Results were considered significant when differences between groups (p) were <0.05.

5. Conclusions

From the results of the present research, it is possible to conclude that the 1,8-naphthyridine derivatives 1,8-NA and 3-TNB do not have intrinsic antibacterial activity against multi-resistant strains. Despite this, the compounds potentiate the effect of fluoroquinolones against E. coli 06, S. aureus 10, and P. aeruginosa 24, and can therefore be considered as adjuvants to antibacterial drugs. Existing evidence suggests that synergistic effects are related to similarity in chemical structure and mechanisms of action.

Supplementary Materials

The following are available online, 7-Acetamido-1,8-naphthyridin-4(1H)-one (1,8-NA) and 3-trifluoromethyl-N-(5-chloro-1,8-naphthyridin-2-yl)-benzenesulfonamide (3-TNB): FTIR SPECTRUM, NMR 1H and 13C besides 19F.

Author Contributions

Conceptualization, J.B.d.A.-N. and S.R.T.; Methodology, J.B.d.A.-N. and M.M.C.d.S.; Validation, I.M.B. and L.E.d.S.; Formal analysis, C.D.d.M.O.-T.; Investigation, J.B.d.A.-N., M.M.C.d.S., I.M.B., R.A.R., S.L.M., M.C.N., M.I.L.K. and L.E.d.S.; Resources, H.D.M.C., A.S. and P.W.; Data curation, C.D.d.M.O.-T.; Writing—original draft preparation, J.R.-F.; Writing—review and editing, J.B.d.A.-N. and J.R.-F.; Supervision, S.R.T.; Project administration, S.R.T. and H.D.M.C.; Funding acquisition, A.S., P.W. and H.D.M.C. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by the National Council of Scientific and Technological Development (CNPq), Process (150456/2018-2 and 406685/2018-5), Coordination for the Improvement of Higher Education Personnel (CAPES) Finance code 001, Cearense Foundation for Scientific and Technological Development Support (FUNCAP) and Financier of Studies and Projects-Brazil (FINEP).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All data and analyses are available in the manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

Sample Availability

Samples of the compounds are available from the authors.

References

  1. Ribeiro Da Cunha, B.; Fonseca, L.P.; Calado, C.R.C. Antibiotic discovery: Where have we come from, where do we go? Antibiotics 2019, 8, 45. [Google Scholar] [CrossRef] [Green Version]
  2. Hutchings, M.I.; Truman, A.W.; Wilkinson, B. Antibiotics: Past, present and future. Curr. Opin. Microbiol. 2019, 51, 72–80. [Google Scholar] [CrossRef]
  3. Jacopin, E.; Lehtinen, S.; Débarre, F.; Blanquart, F. Factors favouring the evolution of multidrug resistance in bacteria. J. R. Soc. Interface 2020, 17, 20200105. [Google Scholar] [CrossRef]
  4. Tacconelli, E.; Carrara, E.; Savoldi, A.; Harbarth, S.; Mendelson, M.; Monnet, D.L.; Pulcini, C.; Kahlmeter, G.; Kluytmans, J.; Carmeli, Y.; et al. Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 2018, 18, 318–327. [Google Scholar] [CrossRef]
  5. Blair, J.M.A.; Webber, M.A.; Baylay, A.J.; Ogbolu, D.O.; Piddock, L.J.V. Molecular mechanisms of antibiotic resistance. Nat. Rev. Microbiol. 2015, 13, 42–51. [Google Scholar] [CrossRef]
  6. Varela, M.F.; Stephen, J.; Lekshmi, J.; Ojha, M.; Wenzel, N.; Sanford, L.M.; Hernandez, A.J.; Parvathi, A.; Kumar, S.H. Bacterial Resistance to Antimicrobial Agents. Antibiotics 2021, 10, 593. [Google Scholar] [CrossRef]
  7. León-Buitimea, A.; Garza-Cárdenas, C.R.; Garza-Cervantes, J.A.; Lerma-Escalera, J.A.; Morones-Ramírez, J.R. The demand for new antibiotics: Antimicrobial peptides, nanoparticles, and combinatorial therapies as future strategies in antibacterial agent design. Front. Microbiol. 2020, 11, 1669. [Google Scholar] [CrossRef]
  8. Saini, M.S.; Kumar, A.; Dwivedi, J.; Singh, R. A review: Biological significances of heterocyclic compounds. Int. J. Pharm. Sci. Res. 2013, 4, 66–77. [Google Scholar]
  9. Walsh, C.T. Nature loves nitrogen heterocycles. Tetrahedron Lett. 2015, 56, 3075–3081. [Google Scholar] [CrossRef]
  10. Taylor, A.P.; Robinson, R.P.; Fobian, Y.M.; Blakemore, D.C.; Jones, L.H.; Fadeyi, O. Modern advances in heterocyclic chemistry in drug discovery. Org. Biomol. Chem. 2016, 14, 6611–6637. [Google Scholar] [CrossRef]
  11. Parhi, A.K.; Zhang, Y.; Saionz, K.W.; Pradhan, P.; Kaul, M.; Trivedi, K.; Pilch, D.S.; LaVoie, E.J. Antibacterial activity of quinoxalines, quinazolines, and 1,5-naphthyridines. Bioorg. Med. Chem. Lett. 2013, 23, 4968–4974. [Google Scholar] [CrossRef]
  12. Gurjar, V.K.; Pal, D.; Mazumder, A.; Mazumder, R. Synthesis, Biological Evaluation and Molecular Docking Studies of Novel 1,8-Naphthyridine-3-carboxylic Acid Derivatives as Potential Antimicrobial Agents (Part-1). Indian J. Pharm. Sci. 2020, 82, 37–42. [Google Scholar] [CrossRef] [Green Version]
  13. Garvey, E.P.; Johns, B.A.; Gartland, M.J.; Foster, S.A.; Miller, W.H.; Ferris, R.G.; Hazen, R.J.; Underwood, M.R.; Boros, E.E.; Thompson, J.B.; et al. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral. Antimicrob. Agents Chemother. 2008, 52, 901–908. [Google Scholar] [CrossRef] [Green Version]
  14. Kumar, V.; Jaggi, M.; Singh, A.T.; Madaan, A.; Sanna, V.; Singh, P.; Sharma, P.K.; Irchhaiya, R.; Burman, A.C. 1,8-Naphthyridine-3-carboxamide derivatives with anticancer and anti-inflammatory activity. Eur. J. Med. Chem. 2009, 44, 3356–3362. [Google Scholar] [CrossRef]
  15. Zhuo, L.S.; Xu, H.C.; Wang, M.S.; Zhao, X.E.; Ming, Z.H.; Zhu, X.L.; Huang, W.; Yang, G.F. 2,7-naphthyridinone-based MET kinase inhibitors: A promising novel scaffold for antitumor drug development. Eur. J. Med. Chem. 2019, 178, 705–714. [Google Scholar] [CrossRef]
  16. Roma, G.; Di Braccio, M.; Grossi, G.; Piras, D.; Ballabeni, V.; Tognolini, M.; Bertoni, S.; Barocelli, E. 1,8-Naphthyridines VIII. Novel 5-aminoimidazo [1,2-a][1,8] naphthyridine-6-carboxamide and 5-amino [1,2,4] triazolo [4,3-a][1,8] naphthyridine-6-carboxamide derivatives showing potent analgesic or anti-inflammatory activity, respectively, and completely devoid of acute gastrolesivity. Eur. J. Med. Chem. 2010, 45, 352–366. [Google Scholar] [CrossRef]
  17. Abu-Melha, S.; Edrees, M.M.; Salem, H.H.; Kheder, N.A.; Gomha, S.M.; Abdelaziz, M.R. Synthesis and biological evaluation of some novel thiazole-based heterocycles as potential anticancer and antimicrobial agents. Molecules 2019, 24, 539. [Google Scholar] [CrossRef] [Green Version]
  18. Hong, C.Y.; Kim, Y.K.; Chang, J.H.; Kim, S.H.; Choi, H.; Nam, D.H.; Yong, Z.K.; Kwak, J.H. Novel Fluoroquinolone Antibacterial Agents Containing Oxime-Substituted (Aminomethyl) pyrrolidines: Synthesis and Antibacterial Activity of 7-(4-(Aminomethyl)-3-(methoxyimino)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic Acid (LB20304), 1. J. Med. Chem. 1997, 40, 3584–3593. [Google Scholar] [CrossRef]
  19. Suresh, T.; Dhanabal, T.; Kumar, R.N.; Mohan, P.S. Synthesis, characterization and antimicrobial activities of fused 1, 6-naphthyridines. Indian J. Chem. 2005, 44, 2375–2379. [Google Scholar] [CrossRef]
  20. Houghton, P.J.; Howes, M.J.; Lee, C.C.; Steventon, G. Uses and abuses of in vitro tests in ethnopharmacology: Visualizing an elephant. J. Ethnopharmacol. 2007, 110, 391–400. [Google Scholar] [CrossRef]
  21. Ezelarab, H.A.; Abbas, S.H.; Hassan, H.A.; Abuo-Rahma, G.E.D.A. Recent updates of fluoroquinolones as antibacterial agents. Arch. Pharmaz. 2018, 351, 1800141. [Google Scholar] [CrossRef]
  22. Drlica, K.; Zhao, X.; Malik, M.; Hiasa, H.; Mustaev, A.; Kerns, R. Fluoroquinolone resistance. In Bacterial Resistance to Antibiotics–From Molecules to Man, 1st ed.; Bonev, B.B., Brown, N.M., Eds.; John Wiley & Sons: Hoboken, NJ, USA, 2019; pp. 125–161. [Google Scholar]
  23. Hooper, D.C.; Jacoby, G.A. Topoisomerase inhibitors: Fluoroquinolone mechanisms of action and resistance. Cold Spring Harb. Perspect. Med. 2016, 6, a025320. [Google Scholar] [CrossRef] [Green Version]
  24. Everson da Silva, L.; Carlos Joussef, A.; Kramer Pacheco, L.; Bibas Legat Albino, D.; Mauricio Camilo Duarte, A.; Steindel, M.; Andrade Rebelo, R. Synthesis and antiparasitic activity against Trypanosoma cruzi and Leishmania amazonensis of chlorinated 1,7- and 1,8-naphthyridines. Lett. Drug Des. Discov. 2007, 4, 154–159. [Google Scholar] [CrossRef]
  25. Nasato, M.C. 1,8-naftiridinas Sulfonamídicas: Obtenção, Caracterização e Avaliação Antiprotozoária e Antifúngica. Master’s Thesis, Fundação Universidade Regional de Blumenau, Blumenau, Brazil, 2017. [Google Scholar]
  26. Singh, S.B.; Kaelin, D.E.; Wu, J.; Miesel, L.; Tan, C.M.; Black, T.; Nargund, R.; Meinke, P.T.; Olsen, D.B.; Lagrutta, A.; et al. Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2). Bioorg. Med. Chem. Lett. 2015, 25, 1831–1835. [Google Scholar] [CrossRef] [PubMed]
  27. Sampson, P.B.; Picard, C.; Handerson, S.; McGrath, T.E.; Domagala, M.; Leeson, A.; Romanov, V.; Awrey, D.E.; Thambipillai, D.; Bardouniotis, E.; et al. Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI). Bioorg. Med. Chem. Lett. 2009, 19, 5355–5358. [Google Scholar] [CrossRef]
  28. Eweas, A.F.; Khalifa, N.M.; Ismail, N.S.; Al-Omar, M.A.; Soliman, A.M.M. Synthesis, molecular docking of novel 1,8-naphthyridine derivatives and their cytotoxic activity against HepG2 cell lines. Med. Chem. Res. 2014, 23, 76–86. [Google Scholar] [CrossRef]
  29. Gençer, H.K.; Levent, S.; Çevik, U.A.; Özkay, Y.; Ilgın, S. New 1,4-dihydro [1,8] naphthyridine derivatives as DNA gyrase inhibitors. Bioorg. Med. Chem. Lett. 2017, 27, 1162. [Google Scholar] [CrossRef]
  30. Da Silva, M.M.; De Araújo-Neto, J.B.; De Araújo, A.C.; Freitas, P.R.; Oliveira-Tintino, C.D.D.M.; Begnini, I.M.; Rebelo, R.A.; Da Silva, L.E.; Mireski, S.L.; Nasato, M.C.; et al. Potentiation of Antibiotic Activity by a Meldrum’s Acid Arylamino Methylene Derivative against Multidrug-Resistant Bacterial Strains. Indian J. Microbiol. 2021, 61, 100–103. [Google Scholar] [CrossRef] [PubMed]
  31. De Morais Oliveira-Tintino, C.D.; Tintino, S.R.; Muniz, D.F.; Dos Santos Barbosa, C.R.; Pereira, R.L.S.; Begnini, I.M.; Rebelo, R.A.; Da Silva, L.E.; Mireski, S.L.; Nasato, M.C.; et al. Do 1,8-naphthyridine sulfonamides possess an inhibitory action against Tet (K) and MsrA efflux pumps in multiresistant Staphylococcus aureus strains? Microb. Pathog. 2020, 147, 104268. [Google Scholar] [CrossRef]
  32. Tintino, S.R.; de Souza, V.C.; Silva, J.; Oliveira-Tintino, C.D.D.M.; Pereira, P.S.; Leal-Balbino, T.C.; Pereira-Neves, A.; Siqueira-Junior, J.P.; da Costa, J.G.; Rodrigues, F.F.; et al. Effect of vitamin K3 inhibiting the function of NorA efflux pump and its gene expression on Staphylococcus aureus. Membranes 2020, 10, 130. [Google Scholar] [CrossRef]
  33. De Morais Oliveira-Tintino, C.D.; Muniz, D.F.; Dos Santos Barbosa, C.R.; Pereira, R.L.S.; Begnini, I.M.; Rebelo, R.A.; Da Silva, L.E.; Mireski, S.L.; Nasato, M.C.; Krautler, M.I.L.; et al. The 1,8-naphthyridines sulfonamides are NorA efflux pump inhibitors. J. Glob. Antimicrob. Resist. 2021, 24, 233. [Google Scholar] [CrossRef]
  34. De Morais Oliveira-Tintino, C.D.; Tintino, S.R.; Muniz, D.F.; Dos Santos Barbosa, C.R.; Pereira, R.L.S.; Begnini, I.M.; Rebelo, R.A.; Da Silva, L.E.; Mireski, S.L.; Nasato, M.C.; et al. Chemical synthesis, molecular docking and MepA efflux pump inhibitory effect by 1,8-naphthyridines sulfonamides. Eur. J. Pharm. Sci. 2021, 160, 105753. [Google Scholar] [CrossRef]
  35. Madaan, A.; Verma, R.; Kumar, V.; Singh, A.T.; Jain, S.K.; Jaggi, M. 1,8-Naphthyridine Derivatives: A Review of Multiple Biological Activities. Arch. Pharmaz. 2015, 348, 837–860. [Google Scholar] [CrossRef]
  36. Leonard, J.T.; Gangadhar, R.; Gnanasam, S.K.; Ramachandran, S.; Saravanan, M.; Sridhar, S.K. Synthesis and pharmacological activities of 1,8-naphthyridine derivatives. Biol. Pharm. Bull. 2002, 25, 798–802. [Google Scholar] [CrossRef] [Green Version]
  37. Martinez, S.R.; Pavani, C.C.; Baptista, M.S.; Becerra, M.C.; Quevedo, M.A.; Ribone, S.R. Identification of the potential biological target of N-benzenesulfonyl-1,2,3,4-tetrahydroquinoline compounds active against gram-positive and gram-negative bacteria. J. Biomol. Struct. Dyn. 2019, 23, 2412–2421. [Google Scholar] [CrossRef]
  38. Coutinho, H.D.M.; De Freitas, M.A.; Gondim, C.N.F.L.; De Albuquerque, R.S.; De Alencar Ferreira, J.V.; Andrade, J.C. In vitro antimicrobial activity of Geraniol and Cariophyllene against Staphylococcus aureus. Rev. Cuba. Plantas Med. 2015, 20, 98–105. [Google Scholar]
  39. Brunton, L.; Chabner, B.; Knollman, B. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 12th ed.; McGraw-Hill: San Diego, CA, USA, 2011; p. 1808. [Google Scholar]
  40. Sampaio, G.M.; Teixeira, A.M.; Coutinho, H.D.; Junior, D.M.S.; Freire, P.T.; Bento, R.R.; Silva, L.E. Synthesis and antibacterial activity of a new derivative of the Meldrun acid: 2,2-dimethyl-5-(4H-1,2,4-triazol-4-ylaminomethylene)-1,3-dioxane-4,6-dione (C9H10N4O4). EXCLI J. 2014, 13, 1022. [Google Scholar]
  41. Gomes, F.M.S.; Da Cunha Xavier, J.; Dos Santos, J.F.S.; De Matos, Y.M.L.S.; Tintino, S.R.; De Freitas, T.S.; Coutinho, H.D.M. Evaluation of antibacterial and modifying action of catechin antibiotics in resistant strains. Microb. Pathog. 2018, 115, 175–178. [Google Scholar] [CrossRef]
  42. Bezerra, C.F.; Camilo, C.J.; Do Nascimento Silva, M.K.; De Freitas, T.S.; Ribeiro-Filho, J.; Coutinho, H.D.M. Vanillin selectively modulates the action of antibiotics against resistant bacteria. Microb. Pathog. 2017, 113, 265–268. [Google Scholar] [CrossRef]
  43. De Sousa Oliveira, F.; De Freitas, T.S.; Da Cruz, R.P.; Do Socorro Costa, M.; Pereira, R.L.S.; Quintans-Júnior, L.J.; Andrade, T.A.; Menezes, P.P.; Sousa, B.M.H.; Nunes, P.S.; et al. Evaluation of the antibacterial and modulatory potential of α-bisabolol, β-cyclodextrin and α-bisabolol/β-cyclodextrin complex. Biomed. Pharmacother. 2017, 92, 1111–1118. [Google Scholar] [CrossRef]
  44. Javadpour, M.M.; Juban, M.M.; Lo, W.C.J.; Bishop, S.M.; Alberty, J.B.; Cowell, S.M.; Becker, C.L.; McLaughlin, M.L. De novo antimicrobial peptides with low mammalian cell toxicity. J. Med. Chem. 1996, 39, 3107–3113. [Google Scholar] [CrossRef]
  45. Coutinho, H.D.; Costa, J.G.; Lima, E.O.; Falcão-Silva, V.S.; Siqueira-Júnior, J.P. Enhancement of the antibiotic activity against a multiresistant Escherichia coli by Mentha arvensis L. and chlorpromazine. Chemotherapy 2008, 54, 328–330. [Google Scholar] [CrossRef]
Molecules 26 07400 g001 550
Figure 1. Antibiotic-modulating activity of 7-acetamido-1,8-naphthyridin-4(1H)-one (1,8-NA) in combination with norfloxacin, ofloxacin, and lomefloxacin against E. coli 06, S. aureus 10, and P. aeruginosa 24. **** Statistical significance: p < 0.0001.
Figure 1. Antibiotic-modulating activity of 7-acetamido-1,8-naphthyridin-4(1H)-one (1,8-NA) in combination with norfloxacin, ofloxacin, and lomefloxacin against E. coli 06, S. aureus 10, and P. aeruginosa 24. **** Statistical significance: p < 0.0001.
Molecules 26 07400 g001
Molecules 26 07400 g002 550
Figure 2. Antibiotic-modulating activity of 3-trifluoromethyl-N-(5-chloro-1,8-naphthyridin-2-yl)-benzenesulfonamide (3-TNB) in combination with norfloxacin, ofloxacin, and lomefloxacin against E. coli 06, S. aureus 10, and P. aeruginosa 24. **** Statistical significance: p < 0.0001; ns: not significant.
Figure 2. Antibiotic-modulating activity of 3-trifluoromethyl-N-(5-chloro-1,8-naphthyridin-2-yl)-benzenesulfonamide (3-TNB) in combination with norfloxacin, ofloxacin, and lomefloxacin against E. coli 06, S. aureus 10, and P. aeruginosa 24. **** Statistical significance: p < 0.0001; ns: not significant.
Molecules 26 07400 g002
Molecules 26 07400 g003 550
Figure 3. Chemical structures of the 1,8-naphthyridine derivatives: (a) 7-acetamido-1,8-naphthyridin-4(1H)-one (1,8-NA); (b) 3-trifluoromethyl-N-(5-chloro-1,8-naphthyridin-2-yl)-benzenesulfonamide (3-TNB).
Figure 3. Chemical structures of the 1,8-naphthyridine derivatives: (a) 7-acetamido-1,8-naphthyridin-4(1H)-one (1,8-NA); (b) 3-trifluoromethyl-N-(5-chloro-1,8-naphthyridin-2-yl)-benzenesulfonamide (3-TNB).
Molecules 26 07400 g003
Molecules 26 07400 g004 550
Figure 4. Chemical structures of the fluoroquinolones: (a) norfloxacin; (b) ofloxacin; (c) lomefloxacin.
Figure 4. Chemical structures of the fluoroquinolones: (a) norfloxacin; (b) ofloxacin; (c) lomefloxacin.
Molecules 26 07400 g004
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Araújo-Neto, J.B.d.; Silva, M.M.C.d.; Oliveira-Tintino, C.D.d.M.; Begnini, I.M.; Rebelo, R.A.; Silva, L.E.d.; Mireski, S.L.; Nasato, M.C.; Krautler, M.I.L.; Ribeiro-Filho, J.; et al. Enhancement of Antibiotic Activity by 1,8-Naphthyridine Derivatives against Multi-Resistant Bacterial Strains. Molecules 2021, 26, 7400. https://doi.org/10.3390/molecules26237400

AMA Style

Araújo-Neto JBd, Silva MMCd, Oliveira-Tintino CDdM, Begnini IM, Rebelo RA, Silva LEd, Mireski SL, Nasato MC, Krautler MIL, Ribeiro-Filho J, et al. Enhancement of Antibiotic Activity by 1,8-Naphthyridine Derivatives against Multi-Resistant Bacterial Strains. Molecules. 2021; 26(23):7400. https://doi.org/10.3390/molecules26237400

Chicago/Turabian Style

Araújo-Neto, José B. de, Maria M. C. da Silva, Cícera D. de M. Oliveira-Tintino, Iêda M. Begnini, Ricardo A. Rebelo, Luiz E. da Silva, Sandro L. Mireski, Michele C. Nasato, Maria I. L. Krautler, Jaime Ribeiro-Filho, and et al. 2021. "Enhancement of Antibiotic Activity by 1,8-Naphthyridine Derivatives against Multi-Resistant Bacterial Strains" Molecules 26, no. 23: 7400. https://doi.org/10.3390/molecules26237400

APA Style

Araújo-Neto, J. B. d., Silva, M. M. C. d., Oliveira-Tintino, C. D. d. M., Begnini, I. M., Rebelo, R. A., Silva, L. E. d., Mireski, S. L., Nasato, M. C., Krautler, M. I. L., Ribeiro-Filho, J., Siyadatpanah, A., Wilairatana, P., Coutinho, H. D. M., & Tintino, S. R. (2021). Enhancement of Antibiotic Activity by 1,8-Naphthyridine Derivatives against Multi-Resistant Bacterial Strains. Molecules, 26(23), 7400. https://doi.org/10.3390/molecules26237400

Article Metrics

Back to TopTop